3 years ago

Cognition enhancing drugs ('nootropics): time to include coaches and team executives in doping tests?

The use of brain boosting drugs by athletes has been well documented and testing for such cognition enhancing drugs is now implemented. Largely absent from the purview of antidoping agencies, however, is the drug testing of coaches and team executives. This editorial introduces commonly used nootropics (drugs that influence cognition) and describes their on-label effects. We then examine the off-label uses of these drugs and consider whether sport organisations, if they are genuinely determined to eliminate performance enhancing drugs among all participants, should also incorporate the testing of coaches and team executives. Advances in sport analytics have changed coaching and executive roles, with decision-making acumen more important than ever.

Brain enhancing drugs including modafinil (Provigil), methylphenidate (Ritalin), and dextroamphetamine (Adderall) were developed to treat sleep problems, attention deficit disorders (ADD), memory deficiencies, and other cognitive maladies.1 Methylphenidate's efficacy is supported by double-blind placebo-controlled trials in the treatment...

Publisher URL: http://bjsm.bmj.com/cgi/content/short/51/18/1316

DOI: 10.1136/bjsports-2015-095474

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.